Journal of Clinical Oncology
Articles in this Issue
Early mortality in patients with advanced non–small cell lung cancer (aNSCLC) and PD-L1 ≥ 50% receiving first-line immune checkpoint inhibitor (ICI): Analysis of the NOTCH collaborative REAL-SAIF study.
e20684 Background: Single-agent ICIs are approved for the first-line treatment of aNSCLC and PDL1 ≥50%. Early cross-over o...
Comparative efficacy of neoadjuvant immunochemotherapy versus chemoradiotherapy in resectable esophageal squamous cell carcinoma: A component network meta-analysis.
e16068 Background: Neoadjuvant chemoradiotherapy (CRT) is the current standard for resectable esophageal squamous cell car...
Trends and disparities in cardiomyopathy-associated mortality among breast cancer adults aged ≥45 years in the United States, 1999–2023: CDC WONDER analysis.
e13141 Background: Breast cancer is the second leading cause of cancer death in the United States (US), with approximately...
Encyclopedic tumor analysis–guided therapy in refractory advanced cancers: Clinical and health-economic outcomes.
e23145 Background: Treatment of relapsed/refractory metastatic cancers costs $128k–$293k per patient with minimal efficacy...
Two-cycle versus three-cycle induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase III randomized noninferiority trial.
6003 Background: Although two- and three-cycle induction chemotherapy are both widely utilized and confer significant surv...
Predictors of treatment (tx) duration in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.
5093 Background: In ARCHES (NCT02677896), ENZA + androgen-deprivation therapy (ADT) significantly improved radiographic pr...
Mortality rates for upper gastrointestinal cancers as a cause or contributing factor in adults aged 45 and older in the United States: A retrospective analysis from 1999-2024.
e16050 Background: Upper Gastrointestinal (UGI) cancers, including esophageal, stomach, and small bowel cancers, have sign...
Personalized N-of-1 combinations based on molecular profiles in advanced malignancies: Immunotherapy group analysis of the I-PREDICT N-of-1 precision oncology study.
2628 Background: While current precision oncology typically targets a single biomarker, most cancers have multiple pathoge...
CircRNA signatures to identify candidate biomarkers of treatment resistance in <i>BRCA1</i> -mutant ovarian cancer.
e17558 Background: Most patients with high grade serous ovarian cancer (HGSOC) ultimately relapse with chemotherapy resist...
AI-powered characterization of the tumor microenvironment landscape in HER2-overexpressing non–small cell lung cancer.
8545 Background: Antibody-drug conjugate (ADC) targeting HER2 in NSCLC is an opportunity for biomarker-guided therapy inde...
Geographic and etiologic heterogeneity of liver cancer in the United States: A comprehensive analysis of prevalence, mortality, DALYs, and risk factors.
e16333 Background: Liver cancer remains a major cause of morbidity and mortality in the United States. Understanding the c...
Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.
4045 Background: Tecotabart vedotin (TV; LM-302) is a novel and potent MMAE-based ADC targeting CLDN18.2. Previous data (A...
A multi-agent AI platform for clinical trial operations: Specialized agents to accelerate feasibility assessment while ensuring data accuracy.
e13646 Background: Clinical trial feasibility assessment typically requires 3-4 weeks of manual data gathering across regu...
Palliative care utilization patterns in chimeric antigen receptor T-cell therapy hospitalizations: A six-year nationwide analysis.
e23165 Background: Chimeric antigen receptor (CAR) T-cell therapy is commonly administered with curative intent for hemato...
Maintenance liposomal doxorubicin following induction doxorubicin in soft tissue sarcoma: A single-center observational study.
e23568 Background: Maintenance chemotherapy prolongs progression-free survival (PFS) in several malignancies, but its role...
Development of a multivariable prognostic model for pathological response using anatomical and pathological variables in early triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: Initial results.
612 Background: The combination of chemotherapy and immune checkpoint inhibitors is the standard of care for most patients...
SWOG S2414 (INSIGHT): A randomized phase III trial incorporating pathologic complete response in participants with early-stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting.
TPS8131 Background: Neoadjuvant chemo-immunotherapy (chemo-IO) followed by surgery is a standard of care for resectable cl...
Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.
2043 Background: Grade 2 diffuse gliomas with isocitrate dehydrogenase 1/2 mutations (mIDH1/2) are incurable brain tumors...
Assessing site-central baseline imaging discordance in oncology clinical trials.
11028 Background: Eligibility determination is a critical and rate-limiting step in oncology clinical trials and directly...
Circulating tumor DNA (ctDNA) from a phase II study of adjuvant dostarlimab with pelvic radiation in locally advanced, mismatch repair–deficient (MMR-D) endometrial cancer (D-RT study).
5613 Background: Although ctDNA is a promising, non-invasive tool for cancer evaluation and monitoring, it’s use in endome...
Temporal trends in ischemic heart disease mortality among lymphoma patients in the United States, 1999–2023: A 25-year nationwide analysis.
7092 Background: Enhanced lymphoma survival has transitioned clinical priorities toward non-malignant late effects, partic...
Fetal-like epithelial niches at the invasive margin to inform prognosis in colorectal cancer.
e15118 Background: The development of metastases remains a major unmet challenge in colorectal cancer (CRC), due to limite...
Electronic health record–based gut disruption and perfluoroalkyl and polyfluoroalkyl substances drinking-water proxies in postmenopausal hormone receptor–positive breast cancer: A nested case-control study.
e24180 Background: Environmental exposures and gut microbiome disruption may influence hormone receptor-positive (HR+) bre...
Cytisinicline for smoking cessation among patients with a history of cancer: A post-hoc analysis from two phase 3 clinical trials.
e22676 Background: Smoking cessation may reduce recurrent and secondary cancers, and extend survival. Cytisinicline, a pla...
Efficacy and safety of mesutoclax (ICP-248) in combination with orelabrutinib in patients with B-cell malignancies: A pooled analysis.
7073 Background: Mesutoclax (ICP-248) is a next-generation BCL2 inhibitor, and orelabrutinib is a marketed BTK inhibitor f...